Patents by Inventor Matthias Dotzauer

Matthias Dotzauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cladribine regimen for treating progressive forms of Multiple Sclerosis
    Publication number: 20230021880
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: September 16, 2022
    Publication date: January 26, 2023
    Applicant: Merck Patent GmbH
    Inventors: Fernando DANGOND, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of Multiple Sclerosis
    Publication number: 20210169912
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 10, 2021
    Applicant: Merck Patent GmnH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of multiple sclerosis
    Patent number: 10849919
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: December 1, 2020
    Assignee: Merck Patent GmbH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of Multiple Sclerosis
    Publication number: 20190167707
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: November 23, 2018
    Publication date: June 6, 2019
    Applicant: Merck Patent GmbH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • CONTINUOUS ADMINISTRATION OF CILENGITIDE IN CANCER TREATMENTS
    Publication number: 20120130146
    Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising the continuous administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agent or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy.
    Type: Application
    Filed: May 25, 2010
    Publication date: May 24, 2012
    Applicant: Merck Patent GmbH
    Inventors: Martin Andreas Picard, Ullrich Bethe, Matthias Dotzauer, Elizabeth Cohen-Jonathan Moyal